<DOC>
	<DOCNO>NCT01689025</DOCNO>
	<brief_summary>This trial conduct Europe United States America ( USA ) . The aim trial investigate safety tolerability NNC0114-0006 subject systemic lupus erythematosus ( SLE ) concomitantly treat stable background therapy .</brief_summary>
	<brief_title>An Investigation Safety Tolerability NNC0114-0006 Subjects With Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Men woman ( pregnant nursing ) Subjects SLE meeting American College Rheumatology ( ACR ) criterion , disease duration least 6 month Subjects clinically active SLE define Safety Estrogens Lupus Erythematosus National Assessment ( SELENA ) Systemic Lupus Erythematosus Disease Activity Index ( SLEDAI ) score least 6 positive antinuclear antibody ( ANA ) and/or Antidoublestranded DNA antibody ( antidsDNA ) If take , background medication must stable Presence history active lupus nephritis ( LN ) within last 4 month active central nervous system ( CNS ) disease within last 12 month Body mass index ( BMI ) 18 kg/m^2 38 kg/m^2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>